Premium
SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY
Author(s) -
Hutchings M,
Mous R,
Clausen M. R,
Johnson P,
Linton K,
Lewis D. J,
Chamuleau M. E.D,
Balari A. S,
Cunningham D,
DeMarco D,
Chen K.M,
Elliott B,
Lugtenburg P
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.16_2879
Subject(s) - medicine , lymphoma , mantle cell lymphoma , refractory (planetary science) , cytokine release syndrome , follicular lymphoma , adverse effect , dosing , diffuse large b cell lymphoma , gastroenterology , oncology , cd20 , cancer , immunotherapy , chimeric antigen receptor , biology , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom